Antisense: Meet The Company Developing Cutting Edge Therapeutics For Rare Diseases

Mark Diamond, CEO of Antisense Therapeutics Limited ANP, was recently interviewed by Benzinga.

Antisense Therapeutics is an Australian publicly-listed biotechnology company developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The company currently has several promising drug candidates in the development pipeline.

ATL1102 is an antisense inhibitor of the CD49d receptor and is intended to treat Duchenne Muscular Dystrophy (DMD) patients. It recently reported highly promising Phase II trial results.  ATL1102 has also successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS). 

Watch the full interview here:

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Featured photo by Hal Gatewood on Unsplash